149 related articles for article (PubMed ID: 20854243)
1. Iatrogenic Creutzfeldt-Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients?
Boyd A; Klug GM; Schonberger LB; McGlade A; Brandel JP; Masters CL; Collins SJ
Med J Aust; 2010 Sep; 193(6):366-9. PubMed ID: 20854243
[TBL] [Abstract][Full Text] [Related]
2. Creutzfeldt-Jakob disease risk in Slovak recipients of human pituitary growth hormone.
Mitrova E; Belay G
Bratisl Lek Listy; 1999 Apr; 100(4):187-91. PubMed ID: 10914140
[TBL] [Abstract][Full Text] [Related]
3. Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone.
Swerdlow AJ; Higgins CD; Adlard P; Jones ME; Preece MA
Neurology; 2003 Sep; 61(6):783-91. PubMed ID: 14504321
[TBL] [Abstract][Full Text] [Related]
4. Lower risk of Creutzfeldt-Jakob disease in pituitary growth hormone recipients initiating treatment after 1977.
Abrams JY; Schonberger LB; Belay ED; Maddox RA; Leschek EW; Mills JL; Wysowski DK; Fradkin JE
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1666-9. PubMed ID: 21816775
[TBL] [Abstract][Full Text] [Related]
5. Managing the risk of iatrogenic transmission of Creutzfeldt-Jakob disease in the UK.
Hall V; Brookes D; Nacul L; Gill ON; Connor N;
J Hosp Infect; 2014 Sep; 88(1):22-7. PubMed ID: 25082752
[TBL] [Abstract][Full Text] [Related]
6. Prion strains associated with iatrogenic CJD in French and UK human growth hormone recipients.
Douet JY; Huor A; Cassard H; Lugan S; Aron N; Mesic C; Vilette D; Barrio T; Streichenberger N; Perret-Liaudet A; Delisle MB; Péran P; Deslys JP; Comoy E; Vilotte JL; Goudarzi K; Béringue V; Barria MA; Ritchie DL; Ironside JW; Andréoletti O
Acta Neuropathol Commun; 2021 Aug; 9(1):145. PubMed ID: 34454616
[TBL] [Abstract][Full Text] [Related]
7. Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States.
Fradkin JE; Schonberger LB; Mills JL; Gunn WJ; Piper JM; Wysowski DK; Thomson R; Durako S; Brown P
JAMA; 1991 Feb; 265(7):880-4. PubMed ID: 1992185
[TBL] [Abstract][Full Text] [Related]
8. A statistical model to identify the contaminated lots implicated in iatrogenic transmission of Creutzfeldt-Jakob disease among French human growth hormone recipients.
Huillard d'Aignaux J; Alpérovitch A; Maccario J
Am J Epidemiol; 1998 Mar; 147(6):597-604. PubMed ID: 9521187
[TBL] [Abstract][Full Text] [Related]
9. Iatrogenic Creutzfeldt-Jakob disease.
Kobayashi A; Kitamoto T; Mizusawa H
Handb Clin Neurol; 2018; 153():207-218. PubMed ID: 29887137
[TBL] [Abstract][Full Text] [Related]
10. [Prevention of prion disease transmission].
Kishida H; Kuroiwa Y
Nihon Rinsho; 2007 Aug; 65(8):1454-9. PubMed ID: 17695283
[TBL] [Abstract][Full Text] [Related]
11. Iatrogenic Creutzfeldt-Jakob disease.
Rappaport EB
Neurology; 1987 Sep; 37(9):1520-2. PubMed ID: 3306455
[TBL] [Abstract][Full Text] [Related]
12. Creutzfeldt-Jakob disease 38 years after diagnostic use of human growth hormone.
Croes EA; Roks G; Jansen GH; Nijssen PC; van Duijn CM
J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):792-3. PubMed ID: 12023427
[TBL] [Abstract][Full Text] [Related]
13. Creutzfeldt-Jakob disease surveillance in Australia January 1970 to December 2003.
Klug GM; Lewis V; Boyd A; Lee JS; Masters CL; Collins SJ
Commun Dis Intell Q Rep; 2004; 28(3):356-8. PubMed ID: 15574060
[TBL] [Abstract][Full Text] [Related]
14. A nationwide cohort study on Creutzfeldt-Jakob disease among human growth hormone recipients.
Wientjens DP; Rikken B; Wit JM; Hofman A; Stricker BH
Neuroepidemiology; 2000; 19(4):201-5. PubMed ID: 10859499
[TBL] [Abstract][Full Text] [Related]
15. Iatrogenic Creutzfeldt-Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients?
Solvyns SL; Ralston DW
Med J Aust; 2011 Feb; 194(4):214-5; author reply 215. PubMed ID: 21401477
[No Abstract] [Full Text] [Related]
16. Creutzfeldt-Jakob disease: Australian surveillance update to 31 December 2004.
Klug GM; Boyd A; Lewis V; Kvasnicka M; Lee JS; Masters CL; Collins SJ
Commun Dis Intell Q Rep; 2005; 29(3):269-71. PubMed ID: 16220862
[TBL] [Abstract][Full Text] [Related]
17. Surveillance of Creutzfeldt-Jakob disease in Australia: 2010 update.
Klug GM; Boyd A; McGlade A; Stehmann C; Masters CL; Collins SJ
Commun Dis Intell Q Rep; 2010 Jun; 34(2):96-101. PubMed ID: 20677418
[TBL] [Abstract][Full Text] [Related]
18. Amyloid-β accumulation in the CNS in human growth hormone recipients in the UK.
Ritchie DL; Adlard P; Peden AH; Lowrie S; Le Grice M; Burns K; Jackson RJ; Yull H; Keogh MJ; Wei W; Chinnery PF; Head MW; Ironside JW
Acta Neuropathol; 2017 Aug; 134(2):221-240. PubMed ID: 28349199
[TBL] [Abstract][Full Text] [Related]
19. [Iatrogenic Creutzfeldt-Jakob disease. Lessons from cases secondary to extracted growth hormone in France].
Billette de Villemeur T; Pradel A
Transfus Clin Biol; 1994; 1(5):333-7. PubMed ID: 7812459
[TBL] [Abstract][Full Text] [Related]
20. Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France.
Huillard d'Aignaux J; Costagliola D; Maccario J; Billette de Villemeur T; Brandel JP; Deslys JP; Hauw JJ; Chaussain JL; Agid Y; Dormont D; Alpérovitch A
Neurology; 1999 Oct; 53(6):1197-201. PubMed ID: 10522872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
